
Rossari Biotech Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 2
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Company targets mid-teen (~15%) top-line growth for the next financial year, excluding CAPEX impact.
- Export turnover expected to grow at 12%-14%, higher than domestic turnover growth forecasted around 10%.
- HPPC division driving robust growth, with volume increases of 30%-35%+ Y-o-Y in recent quarters.
- Institutional Chemicals, Specialty Surfactants (non-agro), and Phenoxy Series see fastest growth within HPPC.
- New product launches and capacity expansions (notably ethoxylation at Dahej) aim to boost volumes.
- CAPEX projects (Rs.180 crore at Dahej) expected to complete by Q3 FY25 leading to significant future sales.
- Textile specialty division currently facing soft demand but expected to recover with domestic/export uptick.
- Biosurfactants production targeted to expand 10x from current 3 tons/month.
- Overall, management confident of sustained volume and revenue growth supported by R&D and capacity expansions.
See what Rossari Biotech management said on margin guidance — free account, 30 seconds.
Fundraise plans
YesSee what Rossari Biotech management said on order book — free account, 30 seconds.
Capex plans
YesTrack Rossari Biotech — get its next earnings analysis in your feed
How does Rossari Biotech rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Rossari Biotech rank in Chemicals & Petrochemicals?
Compare Rossari Biotech against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Rossari Biotech's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…